In the current meta-analysis, we combined the data from 17 studies, including 9764 patients, to determine whether positive TTF-1 expression by IHC can be a surrogate marker for EGFR mutation status in NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.